Zi-Ning Zhang1, Nan Yi, Tong-Wei Zhang, Le-Le Zhang, Xian Wu, Mei Liu, Ya-Jing Fu, Si-Jia He, Yong-Jun Jiang, Hai-Bo Ding, Zhen-Xing Chu, Hong Shang. 1. *Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, China; †Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China; ‡Clinical Laboratory, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; and §Department of Blood Transfusion, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Abstract
OBJECTIVE: Events occurring during the initial phase of human immunodeficiency virus (HIV) infection are intriguing because of their dramatic impact on the subsequent course of the disease. In particular, the relationship between myeloid-derived suppressor cells (MDSCs) and HIV pathogenesis in primary infection remains unknown and the mechanism of MDSCs in HIV infection are incompletely defined. METHODS: The frequency of MDSC expression in patients with primary HIV infection (PHI) and chronic HIV infection was measured, and the association with disease progression was studied. Programmed death-ligand 1 (PD-L1) and galectin-9 (Gal-9) expression on MDSCs was measured and in vitro blocking experiments were performed to study the role of PD-L1 in MDSCs' inhibition. RESULTS: We found increased levels of HLA-DRCD14CD33CD11b granulocytic(G)-MDSCs in PHI individuals compared with normal controls, which correlated with viral loads and was negatively related to CD4 T-cell levels. When cocultured with purified G-MDSCs, both proliferation and interferon-γ secretion by T cell receptor (TCR)-stimulated CD8 T cells from HIV-infected patients were significantly inhibited. We also demonstrated that PD-L1, but not Gal-9, expression on HLA-DRCD14CD33CD11b cells increased during HIV infection. The suppressive activity of G-MDSCs from HIV-infected patients was attenuated by PD-L1 blockade. CONCLUSIONS: We found a significant increase in G-MDSCs in PHI patients that was related to disease progression and PD-L1 was used by MDSCs to inhibit CD8 T cells in HIV infection. Our data improve the understanding of HIV pathogenesis in PHI.
OBJECTIVE: Events occurring during the initial phase of human immunodeficiency virus (HIV) infection are intriguing because of their dramatic impact on the subsequent course of the disease. In particular, the relationship between myeloid-derived suppressor cells (MDSCs) and HIV pathogenesis in primary infection remains unknown and the mechanism of MDSCs in HIV infection are incompletely defined. METHODS: The frequency of MDSC expression in patients with primary HIV infection (PHI) and chronic HIV infection was measured, and the association with disease progression was studied. Programmed death-ligand 1 (PD-L1) and galectin-9 (Gal-9) expression on MDSCs was measured and in vitro blocking experiments were performed to study the role of PD-L1 in MDSCs' inhibition. RESULTS: We found increased levels of HLA-DRCD14CD33CD11b granulocytic(G)-MDSCs in PHI individuals compared with normal controls, which correlated with viral loads and was negatively related to CD4 T-cell levels. When cocultured with purified G-MDSCs, both proliferation and interferon-γ secretion by T cell receptor (TCR)-stimulated CD8 T cells from HIV-infectedpatients were significantly inhibited. We also demonstrated that PD-L1, but not Gal-9, expression on HLA-DRCD14CD33CD11b cells increased during HIV infection. The suppressive activity of G-MDSCs from HIV-infectedpatients was attenuated by PD-L1 blockade. CONCLUSIONS: We found a significant increase in G-MDSCs in PHI patients that was related to disease progression and PD-L1 was used by MDSCs to inhibit CD8 T cells in HIV infection. Our data improve the understanding of HIV pathogenesis in PHI.
Authors: Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis Journal: J Clin Invest Date: 2020-06-01 Impact factor: 14.808
Authors: Daniel Clark Files; Frank Tacke; Alexandra O'Sullivan; Patrick Dorr; William G Ferguson; William G Powderly Journal: PLoS Pathog Date: 2022-06-24 Impact factor: 7.464
Authors: Nicholas K Preiss; Taewook Kang; Young-Kwang Usherwood; Yina H Huang; Bruce R Branchini; Edward J Usherwood Journal: J Immunol Date: 2020-11-13 Impact factor: 5.422
Authors: Luca Cassetta; Kirsten Bruderek; Joanna Skrzeczynska-Moncznik; Oktawia Osiecka; Xiaoying Hu; Ida Marie Rundgren; Ang Lin; Kim Santegoets; Utku Horzum; Ana Godinho-Santos; Gennadiy Zelinskyy; Thalia Garcia-Tellez; Sunčica Bjelica; Bartłomiej Taciak; Astrid Olsnes Kittang; Benedikt Höing; Stephan Lang; Michael Dixon; Verena Müller; Jochen Sven Utikal; Derya Karakoç; Kerim Bora Yilmaz; Emilia Górka; Lubomir Bodnar; Olympia Evdoxia Anastasiou; Christine Bourgeois; Robert Badura; Monika Kapinska-Mrowiecka; Mirjana Gotic; Mark Ter Laan; Esther Kers-Rebel; Magdalena Król; Juan Francisco Santibañez; Michaela Müller-Trutwin; Ulf Dittmer; Ana Espada de Sousa; Güneş Esendağlı; Gosse Adema; Karin Loré; Elisabeth Ersvær; Viktor Umansky; Jeffrey W Pollard; Joanna Cichy; Sven Brandau Journal: J Immunother Cancer Date: 2020-09 Impact factor: 13.751